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Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity
in the beneﬁts of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may aﬀe c tl e f tv e n t r i c u l a r
(LV) remodelling and systolic function. We aimed to assess whether genetic background of maximally treated CHF patients
predicts variations in LV systolic function and volumes. Methods and Results. We prospectively studied 131 CHF outpatients
on optimal treatment for at least six months. Echocardiographic evaluations were performed at baseline and after 12 months.
Genotype analysis for ACE I/D, β1adrenergic receptor (AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu polymorphisms
was performed. No diﬀerences in baseline characteristics were detected among subgroups. ACE II was a signiﬁcant predictor of
improvement of LV end-diastolic and end-systolic volume (P = .003 and P = .002, respectively) but not of LV ejection fraction
(LVEF); β1AR389 GlyGly was related to improvement of LVEF (P = .02) and LV end-systolic volume (P = .01). The predictive
value of polymorphisms remained after adjustment for other clinically signiﬁcant predictors (P<. 05 for all). Conclusions.A C E
I/D and β1AR Arg389Gly polymorphisms are independent predictors of reverse remodeling and systolic function recovery in CHF
patients under optimal treatment.
1.Introduction
Chronic heart failure (CHF) is a major cause of morbidity
and mortality [1]. Approximately 5 million Americans
and more than 10 million Europeans have CHF, with an
incidence approaching 1% of the population among people
over 65 years of age [2]. It is a progressively debilitating
condition and despite treatment, only half of the patients
survive more than ﬁve years after diagnosis [3].
Left ventricular remodeling is a key process determining
disease progression and aﬀecting outcome in this condition.
Several multicenter trials in patients with CHF have shown
a survival beneﬁt from the use of ACE inhibitors, beta-
blockers, and aldosterone antagonists; such eﬀects were
associated with so-called reverse remodeling, in which
the therapy promoted a return to a better left ventricular
size and shape [4–7]. However, signiﬁcant heterogeneity
exists in the beneﬁts to individual subjects. Great attention
has therefore been devoted to the genetic makeup of the
renin-angiotensin-aldosterone system (RAAS) and the beta-
adrenergicsystem:understandingthefunctionalroleofthese
variants is a main aim of current research. One of the most
comprehensively studied polymorphisms is ACE I/D, which
is localized in the ACE gene. The DD genotype is implicated
in numerous pathological conditions considered to be key
risk factors for heart failure [8, 9]. Similarly, polymorphisms
of β a d r e n e r gi cr e c e p t o r sh a v eb e e nr ega r d e da si m p l i c a t e di n
the variation of cardiac response to sympathetic drive. The
aim of the present study was to assess whether the genetic
background of the individual patient might predict changes2 Cardiology Research and Practice
in left ventricular systolic function and volumes within a




with CHF was recruited from the Heart Failure Clinic of
the Cardiology Department at Verona City Hospital. The
local ethics committee approved the protocol and each
patient gave written informed consent before participation
in the study. The criteria for enrollment were a diagnosis
of dilated cardiomyopathy of diverse etiology with a left
ventricularejectionfraction<45%,stableclinicalconditions,
and optimal medical treatment at the maximally tolerated
dosages according to the most recent CHF international
guidelines for at least six months. All subject were followed
up prospectively for one year and underwent two complete
echocardiographic evaluations, at the beginning and at the
e n do ff o l l o w u p .
2.2. Genotyping. A 2mL blood sample was collected in an
EDTA-containing tube and was kept at −80
◦C until the
deoxyribonucleic acid (DNA) was isolated. We identiﬁed the
following polymorphisms: ACE I/D, β1 adrenergic receptor
(AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu. The
gene polymorphisms studied were ampliﬁed using poly-
merase chain reactions (PCRs) and processed by restriction
enzymes when needed. The procedure used to prepare DNA
for PCR from whole blood was based on that described
by Walsh et al. [10] for forensic material. Putative DD
genotypes were further conﬁrmed using the ACE 2 primer,
whicheliminatesmistypingthatcanoccurwithatwo-primer
system. The PCR results were scored by two independent
investigators unaware of patient identity. PCRs were run for
35cycles: 30seconds at 94
◦, 45seconds at 56
◦, and 2minutes
at 72
◦. The product was subjected to electrophoresis in a
1.5% agarose gel and stained with ethidium bromide.
2.3. Statistical Analysis. Data were expressed by mean ±
standard deviation (SD) for continuous variables or by
number and percentage for categorical variables. Intergroup
comparisons of % changes in left ventricular ejection
fraction and volumes (% diﬀerence between end and
beginning of followup: ΔLVEF, ΔLVEDV, ΔLVESV) were
made using Student’s t-test for unpaired data. Univariate
and multivariate logistic regression analyses were used to
determine the relationship between clinical and genetic
variables and ΔLVEF, ΔLVEDV, and ΔLVESV. Commercially
available statistical software was used (Statview 5.0, Abacus
ConceptsInc;SAS6.12,SASInstitute,Cary,NorthCarolina).
A P value < .05 was considered statistically signiﬁcant.
3. Results
3.1. Clinical Characteristics of the Study Population. During
theobservationperiod,sixpatientsdied,andonepatientwas
lost to followup, while ten patients underwent implantation
of a biventricular pacemaker, and were therefore excluded
Table 1: Baseline characteristics of study population.
Variable
Age (yrs) 63.2 ±9
Male gender n (%) 107 (82)
NYHA functional class 2.2 ±0.7
SBP (mm Hg) 127 ±15
DBP (mm Hg) 79 ±8
Heart Rate (beats/min) 67 ±11
S-Na+ (mEq/L) 139 ±3
S-Creatinine (μmol/L) 105 ±25
Hb (g/dL) 13.9 ±1.3
Treatment n (%)
Diuretics 117 (90)
ACE inhibitors/ARBs 127 (97)




LVEF (%) 33 ±7
LVEDV (mL) 266 ±98
LVESV (mL) 181 ±86
Genotypes, n
ACE II/ ID, DD 20/111
β1 AR389 ≥1 Arg/GlyGly 31/100
β21 6G l y G l y /≥ 1 Arg 57/74
β22 7G l n G l n /≥ 1 Glu 51/80
Data are expressed as mean ± SD or number (%). Abbreviations: NYHA:
New York Heart Association; SBP: systolic blood pressure; DBP: diastolic
blood pressure; Hb: hemoglobin; ARBs: angiotensin II receptor blockers;
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end diastolic
volume; LVESV: left ventricular end systolic volume.
from further analyses because of the well-known resyn-
chronization therapy eﬀects on left ventricular remodeling
and systolic function; 131 patients completed the study.
The clinical baseline characteristics of study population are
summarized in Table 1. Most patients were men, aged 63.2 ±
9 years old, and with a CHF of mainly ischemic (60.7%) or
idiopathic origin (34.9%). At baseline mean left ventricular
ejection fraction (LVEF) was 33±7%, mean left ventricular
end-diastolic volume (LVEDV) 266±98mL, and mean left
ventricular end-systolic volume (LVESV) 181±86mL. No
statistically signiﬁcant diﬀerences in baseline characteristics
were detected among the genotype subgroups.
3.2. Echocardiography. At one-year followup mean LVEF was
36±9%; 8% of patients completely recovered their systolic
function with an improvement of LVEF to a value >50%. We
foundthat45%ofpatientshadareductionofLVEDV>10%,
whileonly21%increasedtheirLVEDV>10%.Areductionof
LVESV >10% was found in 47% of subjects, whereas 25% of
patients worsened, showing an increase in volume >10%.
Association between Genetic Polymorphisms and Changes in
LV Function and Volumes.. The relations between geneticCardiology Research and Practice 3
Table 2: Changes in echocardiographic parameters according to
ACE and βAR genotypes.
ΔLVEF ΔLVEDV ΔLVESV
ACE II versus ID, DD 7/3 −16/0∗ −19/0∗
β1AR389 ≥1Arg versus GlyGly 7/−7∗ 16/−3∗ 24/−6†
β2AR16 GlyGly versus ≥1Arg 0/6 −2/−3 −1/−5
β2AR27 GlnGln versus ≥1Glu 3/0 −3/−3 −4/−3
ΔLVEF (left ventricular ejection fraction), ΔLVEDV (left ventricular end
diastolic volume), and ΔLVESV (left ventricular end systolic volume) are
calculated as the percentage diﬀerence between followup and baseline left
ventricular ejection fraction and volumes, respectively. Comparisons were
made using the Student’s t-test for unpaired data. ∗P<. 05; †P<. 01.





NYHA functional class .04
Diuretic dose (mg) NS
S-Creatinine (μmol/L) NS
Baseline LVEF (%) <.0001
A b b r e v i a t i o n sa si nTable 1.
polymorphisms and variations in LVEF, LVEDV, and LVESV
are described in Table 2.T h eA C EI Ig e n o t y p eh a dar e d u c -
tion of LVEDV and LVESV of 16% and 19%, respectively,
while in ID/DD group there was no signiﬁcant variation
in left ventricular volumes over followup (P<.05 for both
comparisons). β1AR389 GlyGly genotype was related to an
improvement in LVEF of 7%, while the β1AR389 ≥1Arg
group showed a decrease of 7% (intergroup comparison
P<.05). Moreover, β1AR389 ≥1Arg was associated with a
worsening of ventricular volumes with an LVEDV increase
of 16% and an LVESV increase of 24%, whereas the
β1AR389GlyGlygroupshowedaslightimprovementofboth
LVEDV and LVESV (P<.05 and P<.01, resp., for intergroup
comparisons). Genotypes of the β2AR 16 and β2AR 27
showed no signiﬁcant changes in left ventricular systolic
function or volumes over time.
3.3. Clinical Predictors of Remodeling. At the univariate
analysis, signiﬁcant predictors of improving LVEF were age
(P = .018, r =− 0.13), NYHA class (P = .01, r =− 0.15),
serum creatinine (P = .01, r =− 0.14), diuretic dose (P =
.03, r =− 0.12), baseline LVEF (P = .001, r =− 0.22),
and nonischemic etiology (P = .0003). At the multivariate
analysis, independent clinical predictors of improvement in
systolic function were lower NHYA class, lower baseline
LVEF,andnonischemicetiology(Table 3).Signiﬁcantclinical
predictors of changes in left ventricular volumes were
systolicbloodpressure,baselineLVEDV,andbaselineLVESV,
while at the multivariate analysis independent predictors
of ΔLVEDV were only higher values of baseline LVEDV
(P = .0006) and baseline LVESV (P = .004); systolic blood
pressure was the only independent predictor of ΔLVESV
(P = .04).
3.4. Genetic Predictors of Remodeling. ACE I/D was signiﬁ-
cantly correlated with ΔLVEDV and ΔLVESV, while we did
not observe any association with ΔLVEF (Table 4). At the
multivariate analyses it was signiﬁcantly and independently
related to both ΔLVEDV (P = .03) and ΔLVESV (P = .028),
even after adjustment for baseline left ventricular volumes
and systolic blood pressure. β1AR 389 was associated with
both ΔLVEF and ΔLVESV, but not with ΔLVEDV. At the
multivariate analyses it proved a signiﬁcant predictor for
both ΔLVEF (P = .03) and ΔLVESV (P = .02), even after
adjustmentforetiology,NYHAclass,baselinevaluesofLVEF,
and LVESV and systolic blood pressure (P<. 05 for both).
β2AR 16 was only a borderline predictor of ΔLVEF at the
univariate analysis, but lost its power at the multivariate
analysis, while β2AR 27 was not associated with reverse
remodeling or improvement in systolic function (Table 4).
4. Discussion
In the present study we analyzed the impact of genetic poly-
morphisms of the β adrenergic system and RAAS on ventric-
ular remodeling and systolic function in a population of 131
CHFoutpatientswhohadalreadybeenonoptimaltreatment
for this condition for at least six months. Interestingly, at
one year followup, we observed a signiﬁcant improvement
in left ventricular volumes and systolic function in about
half and one fourth of patients, respectively. Importantly,
along with clinical predictors of reverse remodeling and
systolic function recovery such as baseline conditions and
CHF etiology, we found that ACE I/D and β1AR 389
polymorphisms were independent predictors of functional
and/or volumetric improvement, suggesting an important
genetic background to disease progression and response to
therapy. Because the beneﬁts in terms of remodeling of beta
blockers and ACE inhibitors are already evident after only
three months of treatment [11, 12], to ﬁnd an improvement
after one year in subjects who had already been on optimal
treatment for at least six months is a very remarkable result.
4.1. ACE Polymorphism. The ACE gene I/D polymorphism
is one of the most comprehensively studied genetic variants
in the ﬁeld of cardiovascular disease. This polymorphism
consists of the insertion (I) or deletion (D) of a 287-bp
DNA fragment in intron 16 of the ACE gene. Serum and
cardiac tissue levels of ACE and angiotensin II are related
to ACE I/D polymorphism, with lower activation of RAAS
in II subjects [13–15]. Previous studies report increased
prevalence of DD genotype in CHF patients as compared
with controls [16] and the same genotype is associated
with increased mortality in patients with CHF [17]. In
the present study we found that ACE gene polymorphism
is a good predictor of left ventricular remodeling, being
signiﬁcantly, and independently related to both ΔLVEDV
and ΔLVESV, even after adjustment for baseline values
of volumes. The II genotype was signiﬁcantly correlated4 Cardiology Research and Practice
Table 4: Genetic predictors of echocardiographic changes at one year followup (univariate and multivariate analyses, see text for details).
Genotypes Univariate analysis P-value Multivariate analysis P-value
ΔLVEF ΔLVEDV ΔLVESV ΔLVEF ΔLVEDV ΔLVESV
ACE II versus. ID/DD NS NS .003 — .03 .028
β1AR389 ≥ 1Arg versus GlyGly .02 .02 NS .03 NS .02
β 2AR16 GlyGly versus ≥ 1Arg .05 .05 NS NS NS NS
β 2AR27 GlnGln versus ≥ 1Glu NS NS NS NS NS NS
A b b r e v i a t i o n sa si nTable 1.
with an improvement in left ventricular volumes, with a
reduction of both LVEDV and LVESV. This observation
is in accordance with previous studies from our group
showing a genotype-dependent response to ACE-inhibitors
and spironolactone in CHF patients [18, 19]. Nevertheless,
even in the most unfavourable genetic conditions there is
an important eﬀect on disease progression of inhibition
with maximal pharmacological therapy for CHF, as shown
by the stability of left ventricular volumes in the majority
of patients. Previous studies investigating the association
between the ACE genotype and cardiac function in CHF
patients assessed the negative impact of the DD group.
McNamara et al. [20] evaluated the interaction between
ACE inhibitor therapy and the eﬀect of the ACE genotype
on survival, ﬁnding that higher doses of ACE inhibitors
diminished the impact of the ACE D allele. Our results
further suggest the presence of a pathophysiological pathway
from the ACE gene to increased levels of ACE and variations
in cardiac function, supporting the hypothesis that ACE
genotype modulates the progression and response to therapy
in CHF.
4.2. β1AR 389 Polymorphism. The β1AR is the predomi-
nant β-adrenergic receptor expressed on the cardiomyocyte
and is responsive to circulating epinephrine and to local
norepinephrine derived from cardiac sympathetic nerves
[21]. Two common polymorphisms of β1AR in the human
population lead to either a glycine (β1AR Gly389) or an
arginine (β1AR Arg389) at amino acid position 389, where
the latter variation is characterized by increased function.
The β1AR Arg389 polymorphism has been therefore con-
sidered a possible risk factor for heart failure, since it
results in an increase of approximately 200% in agonist-
stimulated activity in transfected cells as compared with the
β1AR Gly389 receptor [22]. Its synergic eﬀect with other
polymorphisms has been estimated to represent some degree
of increased risk of CHF, whereas the β1AR Arg389 genotype
alone was not associated with heart failure [23]. In the
present study we found that β1AR Arg389 genotype is an
independent predictor of worsening systolic function and
LVESV, while the β1AR Gly389 genotype was not associated
with substantial changes.
Previous studies investigating the potential relation-
ship between genotype and response to beta-blockers have
reported contrasting results. Some have found no eﬀect of
beta adrenergic system polymorphisms on survival in CHF
patients treated with beta blockers [24, 25]. Chen et al. [26]
found that after treatment with carvedilol, patients with
Arg/Arg genotype had a signiﬁcantly greater improvement
in LVEF compared to Gly389 carriers, whereas there were
no diﬀerences attributable to other β1a n dβ2 adrenergic
receptor polymorphisms. Taken together, these observations
suggest that the β1AR Arg389 genotype could play a key
role in promoting remodeling of the left ventricle, even in
conditions of maximal medical therapy, and could identify
patients at particularly high risk. Nevertheless, it should be
said that this genotype characterises a minority of CHF
patients, probably too few to allow extensive evaluation of
the eﬀect of the polymorphism on progression of CHF.
4.3. β2P o l y m o r p h i s m .β2 receptors are also implicated in
adrenergic signalling, even though norepinephrine released
fromsympatheticnervesshowsamuchloweraﬃnitytothese
receptors than to β1. Our results revealed how β2AR Gly16
genotype is a borderline predictor forvariation in LVEF (P =
.05),whileβ2AR27polymorphism isnotsigniﬁcantlyrelated
to either systolic function or volumetric variation.
It is important to emphasize that in a highly progressive
disease like CHF, most patients on standard treatment for
this condition remained stable or even underwent a func-
tional and volumetric improvement. Moreover, a signiﬁcant
percentage of patients had a complete recovery of systolic
function. Many studies have already explored genotypes of
RAAS and the adrenergic system as possible risk factors
for CHF. In this research we rather analyzed how genetic
background is related to progression of CHF, and found
that functional and volumetric improvements were at least
in part and independently related to genetic polymorphisms
of neurohormonal systems. Understanding the mechanisms
underlying the pharmacogenetic interaction between poly-
morphisms and treatment could predict which patients will
respond best to beta-blockers and ACE inhibitors. Gene
variation analyses will probably never completely preﬁgure
drug responsiveness in a complex condition like CHF, but
hopefully in the future they could help to select patients
for treatment in a more speciﬁc way, evaluating ethnic and
interindividual diﬀerences.
Our study has some limitations. The main one is the
modest number of subjects in a few genotype groups.
Because of the diﬀerent frequencies of alleles in the pop-
ulation, several polymorphisms are diﬃcult to recruit for
investigation. To measure the impact of genetic variation in
a multifactorial disease in which heterogeneous mechanisms
and numerous interactions are implicated, larger trials are
certainly needed. Moreover, analysis of the duration of the
disease will be necessary, since the progression of CHFCardiology Research and Practice 5
and response to therapy are modulated by the grade of
hypertrophy and interstitial ﬁbrosis [27–29].
In conclusion, our results indicate that stable and
maximally treated patients with CHF can improve their
left ventricular systolic function and volumes according to
speciﬁc baseline clinical and genetic variables. Some genetic
variationsmaybemoreimportant intheprogression ofCHF
than in its predisposition. Therefore, genetic polymorphisms
could indeed be at least in part responsible for interindi-
vidual variation in progression of the disease as well as in
response to therapy; whether genotyping may help to target
therapy and improve clinical management of CHF patients
can only be conﬁrmed by large, randomized trials.
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